Читать книгу Assisted Reproduction Techniques - Группа авторов - Страница 99

1 1 Logan S, Perz J, Ussher JM, Peate M, Anazodo A. Systematic review of fertility‐related psychological distress in cancer patients: Informing on an improved model of care. Psychooncology. 2019; 28(1):22–30.

2 2 Poorvu PD, Frazier AL, Feraco AM, Manley PE, Ginsburg ES, Laufer MR, LaCasce, AS, Diller LR, Partridge AH. Cancer treatment‐related infertility: a critical review of evidence. JNCI Cancer Spectrum. 2019;3(1).

3 3 Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, Robison L, Sklar CA. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006; 91(5):1723–28.

4 4 Andersen CY, Mamsen LS, Kristensen SG. Fertility preservation, freezing of ovarian tissue and clinical opportunities. Reproduction. 2019; 158:27–34.

5 5 Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017; 377(17):1657–65.

6 6 Beckmann MW et al. Concept paper on the technique of cryopreservation, removal and transplantation of ovarian tissue for fertility preservation. Geburtshilfe Frauenheilkd. 2019; 79(1):53–62.

7 7 Lotz L, Dittrich R, Hoffmann I, Beckmann MW. Ovarian tissue transplantation: experience from Germany and worldwide efficacy. Clin Med Insights: Reprod Health. 2019;( 13):1–8.

8 8 Gellert SE, Pors SE, Kristensen SG. Transplantation of frozen‐thawed ovarian tissue: an update on worldwide activity published in peer‐reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018; 35(4):561–70.

9 9 Grynberg M, Mayeur L, Hesters L, Gallot V, Frydman N. First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer. Annals of Oncology. 2020; 31(4):541–2.

10 10 Youssef M, Van Der Veen F, Al‐Inany Mochtar M, Griesinger G, Mohesen M, Aboulfoutouh I, van Wely M. Gonadotropin‐releasing hormone agonist versus hcg for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database Syst Rev. 2014; 31(10).

11 11 Oktay K, Turkcuoglu I, Rodriguez‐Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed. 2010; 20(6):783–8.

12 12 Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, Gilchrist RB, Walters KA, Abbott JA. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017; 32(5):1033–45.

13 13 Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009; 360(9):902–11.

14 14 Argyle CE, Harper JC, Davies MC. Oocyte cryopreservation: where are we now? Hum Reprod Update. 2016; 22(4):440–9.

15 15 Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009; 18(6):769–76.

16 16 Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta analysis. J Womens Health (Larchmt). 2009; 18(3):311–9.

17 17 Ben‐Aharon I, Gafter‐Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta‐analysis. Breast Cancer Res Treat. 2010; 122(3):803–11.

18 18 Blumenfeld Z, von Wolff M. GnRH‐analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update. 2008; 14(6):543–52.

19 19 Beck‐Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update. 2008; 14(6):553–61.

20 20 Chen H, Xiao L, Li J, Cui L, Huang W. Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women. Cochrane Database of Syst Rev. March 2019.

21 21 Dohle GR. Male infertility in cancer patients: review of the literature. Int J Urol. 2010; 17(4):327–31.

22 22 Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta‐analysis. Fertil Steril. 2006; 86:70–80.

23 23 The Practice Committee of the Society for Assisted Reproductive Technology and the Practice Committee of the American Society for Reproductive Medicine. Essential elements of informed consent for elective oocyte cryopresevation: a Practice Committee opinion. Fertil Steril. 2008;90:134–5.

24 24 Goldman RH, Racowsky C, Farland LV, Munné S, Ribustello L, Fox JH. Predicting the likelihood of live birth for elective oocyte cryo‐ preservation: a counseling tool for physicians and patients. Hum Reprod. 2017; 32:853–9.

25 25 Aflatoonian N, Pourmasumi S, Aflatoonian A, Eftekhar M. Duration of storage does not influence pregnancy outcome in cryopreserved human embryos. Iran J Reprod Med. 2013; 11(10):843–6.

26 26 Turkgeldi L, Cutner A, Turkgeldi E, Al Chami A, Cassoni A, Macdonald N, Mould T, Nichol A, Olaitan A, Saridogan E. Laparoscopic ovarian transposition and ovariopexy for fertility preservation in patients treated with pelvic radiotherapy with or without chemotherapy. Facts Views Vis Obgyn. 2019; 11(3):235–42.

27 27 Terenziani M, Piva L, Meazza C, Gandola L, Cefalo G, Merola M. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril. 2009; 91(3):15–6.

28 28 Morice P, Thiam‐Ba R, Castaigne D, Haie‐Meder C, Gerbaulet A, Pautier P, Duvillard P, Michel G. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. Hum Reprod. 1998; 13(3):660–3.